

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
September 16, 2021
MO HealthNet
VIA WEBEX ONLY

Committee Members Present:

Conrad Balcer, DO, Chair
Laura Kingsley, PharmD
Morgan Sperry, PharmD
Angeline Stanislaus, MD
J.K. Sturgeon, PharmD, BCPS

Committee Members Absent:

Matthew Stinson, MD

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations Manager
Elizabeth Sissom, RN, Clinical Management
Lisa E. Smith, Program Development Specialist
Timothy Kling, MD, Acting Medical Director
Elizabeth Short, Program Development Specialist
Connie Sutter, Fiscal Manager
Keri Ballew, Drug Rebate Unit Supervisor
Olivia Rush, PharmD, Program Integrity Pharmacist
Ambra Stotler, Benefit Program Senior Specialist
Jaime Jones, Drug Rebate Medicaid Specialist

Contractors in Attendance:

April Ash, PharmD, Conduent
Blake Shrouf, PharmD, AAHIVP, Conduent
Jennifer Colozza, PharmD, Conduent
Karen Powell, PharmD, Conduent
Luke Boehmer, PharmD, Conduent
Megan Fast, PharmD, Conduent
Serena Barden, PharmD, BCPS, Conduent
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Valerie Schmitz, RN, BSN Wipro

Others Attending:

Aaron Shaw
Alex Kantorovich
Ann Willet
Anne DePriest
Audrey Rattan
Brian Strickland
Brooke Wilkins
Camille Kerr
Chris Stanfield
Chris VandeVen
Dave Poskey
David Large
David Walker
Doug Wood
Eric Berthelot
Erin Hohman
Folger Tuggle
Frank Alvarado

Gina Heinen
Harvey Serota
Jessica Petrie
Jill Frandeen
Jim Fleming
JJ Roth
Joe Payne
John Bullard
Jonathan Buckner
Jonathan Leesman
K Gulley
Karen Floeder
Kevin Hinthorne
Kurt Hendrickson
Mandy Schnelten
Marilyn Semenchuk
Mark Kaiser
Maureen Mealy
Melissa Basil
Michael Holmes
Michele Shirley
Patrick Harvey
Peter Barrio
Phillip King
Rebecca Abt
Rob Kilo
Roberto Pedraza
Sean Jones
Shauna Williams
Stormy Cameron
Tami Sova
Tracy Pellegrino

<p>Welcome, Introductions and Opening Remarks</p>	<p>Conrad Balcer, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with new DPAC committee member J.K. Sturgeon. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the June 2021 meeting.</p> <p>Decision: The committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July 2021 Eligibles by Group - July 2021 Expenditures by Enrollment Group - July 2021 Expenditures by Service - FY22 Pharmacy Spend vs July 2021 Total Medicaid Spend - FY22 Pharmacy Expenditures - Top 4 Drug Classes per FY22 - Pharmacy Expenditures/Eligibles per FY (2015 – 2021) - Hep C Spend and Utilization FY18 – FY22 - Synagis Expenditures FY19 – FY22 - FY19 – FY22 Rare Disease Expenditures - Streamlining older edits to help decrease call volume to the helpdesk and overall enhanced workflow for all those involved - Updates to opioid policy will be forthcoming at the December DPAC meeting - Pharmacist Provider Services – rule making process and hoping for state fiscal year 2023 implementation
<p>Old Business</p>	
<p>Old Business</p>	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>

New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - Public comment provided by: <ul style="list-style-type: none"> o Ann Willet with Pfizer on Myfembree <p>Decision: The committee voted to accept the presented new drug recommendations with no revisions.</p>
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Emsam Clinical Edit o Immunoglobulin Clinical Edit o Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit o Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit o Nuedexta Clinical Edit o Oxandrin Clinical Edit o Palforzia Clinical Edit o Ranexa Clinical Edit o Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit o Xcopri Clinical Edit - Public comment provided by: <ul style="list-style-type: none"> o Maureen Mealy with Horizon on Uplizna <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Aduhelm Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Tami Sova with Biogen <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Botulinum Toxin Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Equetro Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Narcolepsy Inhibitors Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Psychotropic Medications Polypharmacy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Selective Serotonin Reuptake Inhibitor (SSRI) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose around the diagnosis list mentioned in the proposal – it was explained that the list was too extensive to include on the proposal - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Preferred Drug List Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o ARBs and ARBs/Diuretic Combinations o ARBs/CCB Combinations o Beta Blockers and Beta Blockers/Diuretic Combinations o Calcium Channel Blockers, Dihydropyridine o Calcium Channel Blockers, Non-Dihydropyridine o Direct Renin Inhibitors and Combinations o Dry Eye Disease Agents o Niacin Derivatives o PAH, ETAs o PAH, Prostacyclins Inhaled o PAH, Prostacyclins Oral o Sympatholytics - Public comment provided by: <ul style="list-style-type: none"> o Alex Kantorovich with United Therapeutics on Tyvaso in the PAH, Prostacyclins Inhaled PDL Edit o Anne DePriest with Janssen on Uptravi in the PAH, Prostacyclins Oral PDL Edit <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">ACE Inhibitors and ACE Inhibitors/Diuretic Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ACE Inhibitors/Calcium Channel Blocker Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ADHD, Amphetamines Long/Short Acting; Methylphenidate Long/Short Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">ADHD, Non-Stimulants</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Patrick Harvey with Supernus Pharmaceuticals on Qelbree <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p style="text-align: center;">Anticoagulants</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the indications for Xarelto 2.5mg; after discussion the following criteria change was proposed: <ul style="list-style-type: none"> o For Xarelto 2.5 mg: documented diagnosis of coronary artery disease (CAD) or peripheral artery disease (PAD) (with concurrent utilization of aspirin 81 mg daily) - Public comment provided by: <ul style="list-style-type: none"> o Harvey Serota with St. Louis Heart and Vascular on Xarelto o Anne DePriest with Janssen on Xarelto <p>Decision: The Board voted to accept the recommended criteria with the additional revisions above in blue.</p>
<p style="text-align: center;">Anticonvulsants, Rescue Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Antiplatelets</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Homozygous Familial Hypercholesterolemia (HoFH) Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the appropriate LDL levels required for use of therapy along with the need for genetic testing for diagnosis. - Public comment provided by: <ul style="list-style-type: none"> o Tracy Pellegrino with Regeneron Pharmaceuticals on Evkeeza <p>Decision: The Board voted to table the recommended criteria due to the need of a further review of the appropriate LDL levels and need for genetic testing for diagnosis.</p>

<p>PAH, PDE5/SGC Stimulators</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>PAH, Prostacyclins Injectable</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>PCSK9 Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Proton Pump Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Statins (HMG-CoA Reductase Inhibitors) and Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Triglyceride Lowering Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and December meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 4th Quarter 2021 (April, May, June) - Top 25 Drugs by Paid Number 4th Quarter 2021 (April, May, June) - Call Center User Statistics August 2021 - CyberAccess Logging Information - New Drug Statistics August 2021
<p>Adjournment</p>	<p>Morgan Sperry motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via hybrid meeting (in person for MHD, board members, contractors, and WebEx for all others) on Thursday, December 16, 2021.</p>

Roll Call for September 16, 2021						
	<u>Committee Member</u>					
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon
June 2021 Minutes	Y	SY	MY	Y	A	Y
New Drug Review	Y	SY	Y	MY	A	Y
Clinical/Fiscal Edit – No Changes	Y	MY	Y	SY	A	Y
Aduhelm	Y	MY	SY	Y	A	Y
Botulinum Toxin	Y	Y	MY	SY	A	Y
Equetro	Y	MY	Y	SY	A	Y
Narcolepsy Inhibitors	Y	SY	Y	MY	A	Y
Psychotropic Medications Polypharmacy	Y	MY	Y	SY	A	Y
Selective Serotonin Reuptake Inhibitor (SSRI)	Y	SY	Y	MY	A	Y
Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)	Y	MY	Y	SY	A	Y
Preferred Drug List Edits With No Annual Changes	Y	MY	Y	SY	A	Y
PAH, Prostacyclins Oral	Y	MY	SY	Y	A	Y
ACE Inhibitors and ACE Inhibitors/Diuretic Combinations	Y	MY	Y	SY	A	Y

Roll Call for September 16, 2021						
	<u>Committee Member</u>					
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon
ACE Inhibitors/Calcium Channel Blocker Combinations	Y	MY	Y	SY	A	Y
ADHD, Amphetamines Long/Short Acting; Methylphenidate Long/Short Acting	Y	SY	Y	MY	A	Y
ADHD, Non-Stimulants	Y	SY	Y	MY	A	Y
Anticoagulants	Y	Y	SY	MY	A	Y
Anticonvulsants, Rescue Agents	Y	MY	Y	SY	A	Y
Antiplatelets	Y	MY	SY	Y	A	Y
Homozygous Familial Hypercholesterolemia (HoFH) Agents	Y	SY	Y	Y	A	MY
PAH, PDE5/SGC Stimulators	Y	Y	MY	SY	A	Y
PAH, Prostacyclins Injectable	Y	MY	Y	SY	A	Y
PCSK9 Inhibitors	Y	SY	MY	Y	A	Y
Proton Pump Inhibitors	Y	MY	Y	Y	A	SY
Statins (HMG-CoA Reductase Inhibitors) and Combinations	Y	SY	Y	MY	A	Y
Triglyceride Lowering Agents	Y	SY	Y	MY	A	Y

Roll Call for September 16, 2021						
	<u>Committee Member</u>					
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon
Motion to Close	Y	SY	MY	Y	A	Y
Adjournment	Y	SY	Y	MY	A	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain